Looking for a Sinemet attorney in District of Columbia? Get in touch with one of our Sinemet attorneys in District of Columbia now.
Sinemet - News Articles
-
May 6, 2008
Healthcare Republic -
The cells produce levodopa, a precursor of dopamine, and reduced symptoms of tremor, rigidity and balance. Prenatal paracetamol link to wheeze and asthma. Using paracetamol in pregnancy could cause wheezing and asthma in children, a study of more than 60,000 pregnant women ... -
May 12, 2008
Insider Medicine, Canada -
that if these patients had electrodes placed closer to the subthalamic nucleus motor activity improved by 60% and need for levodopa fell by over 50%. From Detroit - Glaucoma patients with poor health literacy, that is the ability to read ... -
May 12, 2008
DG News -
CHICAGO -- May 12, 2008 -- A study of patients with Parkinson's disease suggests that those who have poor results following the implantation of electrodes to stimulate the brain may benefit from additional surgery to correct the electrode placement, according to a report in ... -
May 12, 2008
Washington Post, United States -
MONDAY, May 12 (HealthDay News) -- A few millimeters can make a huge difference for Parkinson's patients treated with electrodes surgically implanted in the r Post Co. Websites © Copyright ... -
May 12, 2008
Science Daily (press release) -
ScienceDaily (May 12, 2008) — A study of seven patients with Parkinson's disease suggests that those who have poor results following implantation of ... -
May 12, 2008
Reuters -
NEW YORK (Reuters Health) - Patients with Parkinson's disease who have a poor response to brain stimulation therapy may improve if the electrodes are repositioned, even by just a few millimeters. A ... -
May 27, 2008
SanFranciscoSentinel.com, CA -
greatly improved when they painted or listened to music (in the years before the gold-standard Parkinson’s medication, levodopa, was available). PDF also recognized Mel and Carol Taub and family, who were instrumental in the gala’s success and Dr. Lewis ... -
May 9, 2008
ABN Newswire (press release), Australia -
Espoo, Finland, May 9, 2008 - (ABN Newswire) - Orion Corporation has decided not to continue the development of their new COMT inhibitor, which has now progressed to the end of clinical Phase I. Based on the overall results received from the studies hitherto the ... -
May 12, 2008
Medi News Direct, India -
Disease stage, severity of PD symptoms and levodopa responsiveness were the parameters considered for patient selection. Following a 4-year evaluation (6-10 ... -
May 9, 2008
Tehran Times, Iran -
Spheramine can be implanted in the brain, where the eye cells naturally begin to produce levodopa. The researchers believe the levodopa is then turned into dopamine, a neurotransmitter lacking in people with Parkinson's. ""Spheramine is not stem cells. There's no requirement for ...
-
May 7, 2008
Business Wire (press release), CA -
SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today its financial results for the first quarter ended March 31, 2008. Revenues for the quarter were $15.0 million, compared to $16.5 million for ... -
Jun 21, 2007
Earthtimes.org -
SAN DIEGO, Ca. and CAMBRIDGE, Mass., June 21 -- Ceregene, Inc. and Genzyme Corporation today announced that they have entered into a partnership for the development and commercialization of CERE-120, Ceregene's proprietary lead program for the treatment of Parkinson's disease.Under the terms of the ... -
Jun 21, 2007
Trading Markets, CA -
(RTTNews) - Genzyme (GENZ | charts | news | PowerRating) announced that it has partnered with Ceregene for the development and commercialization of CERE-120 , Ceregene's proprietary lead program for the treatment of Parkinson's disease. The company noted that as per the terms of ... -
Jun 21, 2007
Boston Business Journal, USA -
Genzyme Corp. will pay at least $25 million as part of a partnership with a California company to develop and sell a new Parkinson's disease treatment. The Cambridge, Mass.-based company (Nasdaq: GENZ) announced on Thursday that it had inked the deal with San Diego's ... -
Jun 21, 2007
Genetic Engineering News (press release), NY -
Ceregene and Genzyme entered into a partnership for the development and commercialization of Ceregene's Phase II candidate, CERE-120, for the treatment of Parkinson's disease.Under the terms of the agreement, Genzyme will pay Ceregene $25 million upfront in exchange for certain partnership-related ... -
Jun 21, 2007
Therapeutics Daily (subscription) (press release), PA -
BANGALORE (Reuters) - Ceregene Inc. said it entered into a development and commercialization deal with Genzyme Corp. for its drug candidate for Parkinson's ... -
Jun 21, 2007
BioWorld Online, GA -
By Randall Osborne Ceregene Inc. is keeping US and Canadian rights to its Phase II drug for Parkinson's disease and getting $25 million up front plus as much as $125 million in milestone payments, along with 50 percent of worldwide Phase III costs covered, through a ... -
Jun 21, 2007
Reuters -
June 21 (Reuters) - Ceregene Inc. (CEGE.O: Quote, Profile, Research) said it entered into a development and commercialization deal with Genzyme Corp. (GENZ. O: Quote, Profile, Research) for its drug candidate for Parkinson's disease. Under ... -
Jun 21, 2007
Reuters -
By Toni Clarke BOSTON, June 21 (Reuters) - Genzyme Corp. (GENZ.O: Quote, Profile, Research) is expanding its research into gene therapy, a controversial and cutting-edge approach to treating disease which most companies avoid. The company, ... -
Jun 21, 2007
Boston Globe, United States -
Genzyme Corp. will team up with a California company to develop a treatment for Parkinson’s disease that employs gene therapy. Genzyme, a Cambridge biotechnology firm, today said its making a $25 million upfront payment to Ceregene Inc., of San ...
Looking for a Sinemet attorney in District of Columbia? Get in touch with one of our Sinemet attorneys in District of Columbia now.
Pages: 1 2 3 4 5 6 ... Next
